Novo Nordisk reports semaglutide cut obesity rates in young children

The wire

1. 01Novo Nordisk says a trial of semaglutide reduced obesity rates in young children, per Reuters.
2. 02Pediatric use would push prescribing and counselling decisions onto clinicians who have little long-term safety data in this age group.
3. 03Detailed results, dosing and safety data were not reported in the item; the findings come from the sponsor ahead of full publication.

From the source

Novo Nordisk says semaglutide cut obesity rates in young children in trial